Regenerative Medicine of the Retina
- Start date:
- 5 April 2019
- 2 days
- Working as:
- Resident physician, Medical specialist
The retina, as highly specialized creator of sight, is vulnerable to a broad range of monogenic and multifactorial causes of degeneration. As a relatively closed compartment, the eye is on the one hand relatively isolated and immune-privileged from the rest of the body, yet at the same time well-accessible to surgical intervention and a broad range of clinical examinations of its structure and function.
As such, the retina is at the forefront of development of regenerative therapies such as gene therapy and stem cell therapy. Recently, the first-ever FDA-approved gene therapy was admitted to the market, for RPE65-associated retinal degeneration.
This Boerhaave Course ‘Regenerative Medicine of the Retina’ aims to give a state-of-the-art overview of the current options and progress in regenerative treatments for the retina. In this course, national and international experts in the field will cover the spectrum of developing therapies for retinal degeneration, ranging from AAV-mediated gene therapy, antisense oligonucleotide and CRISPR/Cas treatment, to optogenetics and stem cell therapy. In addition, important aspects of translation to clinical application will be discussed.
Course participants are encouraged to submit their research for a poster and/or rapid fire oral presentation. Prizes will be awarded for the best poster and oral presentations.
We look forward to welcoming you to the beautiful city of Leiden, which is located very centrally, within less than 30 minutes travel distance from Schiphol Airport.
Please note that the period of April - May is a very busy touristic seasons because all the bulb fields are flowering.
There will be a big demand of rooms so we advise to make your reservation well in advance.
You can make your reservation by using the following link: https://www.ehp-online.nl/congressubscribe/subscribe?id=3401
|Friday April 5th|
|12:00||Registration and lunch|
|Chairs: Arthur Bergen, Carel Hoyng, Gré Luyten|
|13:00||Welcome and opening|
|13:05||Adverse immune effects during retinal gene therapy
|13:50||Splice modulation therapy using antisense oligonucleotides
|14:10||Retinal RPE transplantation and prospects for the clinic
|14:55||Tea break and poster viewing|
|15:25||Defining clinical endpoints for gene therapy studies
|15:45||Retinal gene therapy vectors
|16:30||Rapid fire (5 abstracts)|
|17:00||Poster session and drinks|
|Saturday April 6th|
|Chairs: Jan Wijnholds, Camiel Boon, Carel Hoyng|
|09:05||How to avoid failure in regenerative treatment trials for age-related macular degeneration
|09:25||Retinal optogenetics gene therapy
|10:10||Transplantation of iPSC-derived retinal tissue
|10:30||Coffee break and poster viewing|
|11:00||Gene editing therapy and prospects for the clinic
|11:45||Retinal organoids as a model for hereditary retinal diseases
|12:05||Challenges in retinitis pigmentosa CRB1 gene therapy
|12:25||Lunch/meet the expert|
|13:30||Rapid fire (4 abstracts)|
|13:50||hiPSC vasculature and vessels on chip
|14:35||Practical management of gene therapy/regenerative treatment trials for retinal dystrophies
LUMCAlbinusdreef 2, 2333 ZA Leiden
Lecture Hall 5
Registration fee: € 315,-
Reduction for residents: € 100,-
Dinner on Friday night: € 25,-
Please submit your abstract here